We take a proactive approach to attracting R&D personnel with strong innovative capabilities and provide essential technical support to enhance our innovation pipeline. R&D staff represent nearly 28.71% of our total workforce, and approximately 47.09% of these professionals hold advanced degrees, including master's or above.

We are dedicated to enhancing innovation through significant investments in research and development, which represent a larger share of operating revenue than the industry standard. This strategic focus on R&D aims to cultivate technological advancement and secure a competitive advantage in the marketplace.

Our R&D center covers over 17,000 square meters and includes a variety of advanced laboratories. Equipped with world-class equipment, these facilities facilitate rigorous scientific inquiry and innovation, supporting the creation of cutting-edge solutions.

We have been granted 65 patents, of which 48 are invention patents.

We have published 8 research papers in the world's top medical journals, including The Lancet and Nature.

In our R&D efforts, we have established partnerships with prominent organizations worldwide, including the National Research Council Canada, BIRD-C, and Vaccitech. These collaborations enhance our innovative capabilities. Additionally, we have initiated joint training programs with esteemed universities such as Peking University and Nankai University to cultivate emerging young professionals equipped for a competitive environment.